Armata Pharmaceuticals received FDA Breakthrough Therapy designation for AP-SA02, an intravenous multi-phage treatment targeting complicated Staphylococcus aureus bacteremia, including MRSA and MSSA. This designation, alongside Fast Track and QIDP statuses, highlights AP-SA02's potential to improve outcomes over current therapies, supported by positive Phase 2 clinical data showing higher cure rates and no relapse in treated patients. Armata plans to start a Phase 3 superiority trial in late 2026, aiming to bring this novel antibacterial therapy to market faster for serious bloodstream infections with high relapse and mortality rates.
CIQ has released Fuzzball 4.3, a platform that enables enterprises to deploy validated open-weight AI models and agents on their existing GPU infrastructure with a single command. This update simplifies operationalizing AI by automatically connecting...
As of September 30, 2026, Societe Generale's share capital consists of 739,264,232 shares with a total of 821,169,560 voting rights. The bank highlights its strong global presence with 110,000 employees serving 27 million clients across 58 countries....
Weyerhaeuser's stock recently dropped to a new 52-week low of $18.31, trading around $18.51, reflecting market pressure. Analysts have mixed views: Seaport Global lowered its price target to $30, Raymond James upgraded to "strong buy" with the same t...
Canadian Utilities and Emera have agreed to merge as equals, creating a larger utility and energy infrastructure company. RBC Capital maintains a 'Sector Perform' rating on Canadian Utilities, indicating expected performance in line with the sector. ...
Domino's Pizza is set to report its Q3 earnings on October 13, 2026, with analysts forecasting earnings per share between $4.33 and $4.36 and revenue around $1.17 billion, a 1.6% increase year-over-year. Investors will watch closely how promotional d...
